Phase I Clinical Trial of Human Anti-PD-L1 Antibody Injection (LDP) in Patients With Advanced Malignant Tumors

  • End date
    Apr 26, 2022
  • participants needed
  • sponsor
    Dragonboat Biopharmaceutical Company Limited
Updated on 23 January 2021


This is a phase I, open-label, multiple-dose, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of LDP in subjects with advanced malignant tumors.


This trial is an open, dose escalation phase I clinical trial study of patients with advanced cancer who have failed standard treatment. The trial is divided into a dose escalation phase and an expansion phase.

Approximately 130 patients will be enrolled in this trial. The dose-increasing phase is about 30 cases, and the expansion stage is about 100 cases.

Condition Advanced Tumors
Treatment Whole Human Anti-PD-L1 Antibody Injection (LDP)
Clinical Study IdentifierNCT03908814
SponsorDragonboat Biopharmaceutical Company Limited
Last Modified on23 January 2021


Yes No Not Sure

Inclusion Criteria

Age 18 (inclusive), regardless of gender
Histologically or cytologically confirmed patients with advanced malignant tumors who fail to receive standard treatment or have no standard treatment or are not suitable for standard treatment at this stage
The estimated survival time is more than 3 months
At least one assessable tumor lesion (solid tumors according to RECIST 1.1, lymphoma according to Lugano 2014)
ECOG physical strength score 0-1
Enough organ function
Blood routine (no blood transfusion or colony stimulating factor (G-CSF)
treatment within 14 days):ANC1.5109 / L, PLT75109 / L, Hb80g/L;Liver function
TBIL1.5ULN, ALT2.5ULN, AST2.5ULN (ALT=5ULN for liver metastasis patients
AST5ULN);Renal function: Cr 1.5 ULN, and creatinine clearance > 50 ml
(according to Croft - Gault formula) Coagulation function: activated partial
thromboplastin time (APTT) 1.5 times ULN, prothrombin time (PT) 1.5 times ULN
international normalized ratio (INR) 1.5 times ULN
\. Eligible patients (male and female) with fertility must agree to use
reliable methods of contraception (hormone or barrier or abstinence) during
the trial period and at least 6 months after the last dose; female patients of
childbearing age are selected before the election. The blood or urine
pregnancy test within the day must be negative
\. Prior to the trial, the subject shall have informed consent to the study
and voluntarily sign a written form of informed consent

Exclusion Criteria

Received radiotherapy, chemotherapy, targeted therapy, endocrine therapy or immunotherapy within 4 weeks before the first administration, or other unlisted clinical trial drug therapy (mitomycin and nitrosourea are at least 6 weeks from the last administration, oral fluorouracil drugs such as tegiol and capecitabine are at least 2 weeks from the last administration, and small molecule targeted drugs are at the last administration). At least 2 weeks, or at least 5 half-lives, whichever is longer
Major organ surgery (excluding puncture biopsy) or significant trauma occurred within 4 weeks before the first administration
Adverse reactions of antineoplastic therapy in the past have not been restored to CTCAE grade 5.01 (except for hair loss and other adverse reactions that the investigator judges have no safety risk)
Brain metastasis, spinal cord compression, cancerous meningitis with clinical symptoms, or other evidence that the metastasis of brain and spinal cord has not yet been controlled, are not suitable for the group judged by the researchers; patients with suspected clinical symptoms of brain or pia mater diseases need to be excluded by CT/MRI examination
Those who have previously received treatment with PD-1 or PD-L1 inhibitors
In the past, immune-related adverse events (> grade 3) have occurred in immunotherapy (irAE, see Appendix 5)
Patients with active or recurrent autoimmune diseases (such as systemic lupus erythematosus, rheumatoid arthritis, vasculitis, etc.)
Current or previous patients with interstitial lung disease
Uncontrolled active infections
History of immunodeficiency, including positive HIV antibody test
Patients with active hepatitis B (HBV titer higher than detection limit) ; hepatitis C virus infection
Those with a history of serious cardiovascular disease
Patients with other serious systemic disease history who are judged to be unsuitable for clinical trials
Alcohol or drug dependence is known
Mental disorder or poor compliance
Pregnant or lactating women
Acceptance of live attenuated vaccine within 4 weeks before the first administration or during the study period is planned
Researchers believe that there are any abnormal clinical or laboratory examinations or other reasons in the subjects and that they are not suitable for this clinical study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note